Wolverine Trading
NVO

Wolverine Trading’s Novo Nordisk NVO Stock Holding History

Wolverine Trading’s Portfolio NVO Stock Details NVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		$534K Sell
9,629
-55,416
-85% -$3.24M ﹤0.01% 3633
2025
Q2 		$4.46M Buy
+65,045
New +$4.42M ﹤0.01% 1133
2025
Q1 		– Sell
-51,009
Closed -$4.21M – 5497
2024
Q4 		$4.37M Buy
51,009
+31,830
+166% +$3.44M ﹤0.01% 1301
2024
Q3 		$2.32M Sell
19,179
-55,874
-74% -$7.45M ﹤0.01% 1583
2024
Q2 		$10.7M Buy
75,053
+35,754
+91% +$4.74M 0.01% 616
2024
Q1 		$5.05M Buy
39,299
+24,384
+163% +$2.9M 0.01% 1024
2023
Q4 		$1.54M Buy
14,915
+1,668
+13% +$165K ﹤0.01% 1903
2023
Q3 		$1.2M Buy
13,247
+105
+0.8% +$9.25K ﹤0.01% 1974
2023
Q2 		$1.03M Buy
13,142
+4,858
+59% +$397K ﹤0.01% 1985
2023
Q1 		$655K Sell
8,284
-15,450
-65% -$1.1M ﹤0.01% 2264
2022
Q4 		$1.61M Buy
23,734
+18,008
+314% +$1.06M ﹤0.01% 1533
2022
Q3 		$287K Buy
+5,726
New +$307K ﹤0.01% 3198
2022
Q1 		– Sell
-4,192
Closed -$215K – 6121
2021
Q4 		$234K Buy
+4,192
New +$227K ﹤0.01% 4480
2021
Q3 		– Sell
-16,536
Closed -$799K – 6735
2021
Q2 		$693K Buy
+16,536
New +$641K ﹤0.01% 3248
2020
Q1 		– Sell
-11,246
Closed -$325K – 5068
2019
Q4 		$325K Sell
11,246
-11,742
-51% -$325K ﹤0.01% 3493
2019
Q3 		$593K Buy
22,988
+6,478
+39% +$164K ﹤0.01% 2457
2019
Q2 		$421K Buy
16,510
+4,238
+35% +$105K ﹤0.01% 2898
2019
Q1 		$321K Sell
12,272
-27,670
-69% -$680K ﹤0.01% 3290
2018
Q4 		$915K Buy
39,942
+12,926
+48% +$287K ﹤0.01% 2049
2018
Q3 		$637K Buy
27,016
+1,840
+7% +$44.9K ﹤0.01% 2822
2018
Q2 		$620K Hold
25,176
– – ﹤0.01% 2799
2018
Q1 		$620K Buy
+25,176
New +$661K ﹤0.01% 2799
2017
Q4 		– Sell
-17,432
Closed -$420K – 5307
2017
Q3 		$420K Sell
17,432
-1,366
-7% -$30.9K ﹤0.01% 2819
2017
Q2 		$399K Buy
18,798
+2,806
+18% +$56.6K ﹤0.01% 2671
2017
Q1 		$270K Buy
+15,992
New +$278K ﹤0.01% 3162

Other funds holding NVO

Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return
F
Folketrygdfondet Oslo Norway, Norway $5.64B AUM 47.16% 1-Year Est. Return
Fayez Sarofim & Co
Fayez Sarofim & Co Houston, Texas $39.1B AUM 15.14% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Wolverine Trading's NVO Position: Q3 2025 in Review

Wolverine Trading reduced its Novo Nordisk (NVO) stake by 85% in Q3 2025, selling an estimated $3.24M and leaving 9,629 shares worth $534K. The position accounts for ﹤0.01% of the portfolio, ranked #3633.

Wolverine Trading first reported a position in NVO in Q1 2017 and has held it in 25 quarters since. The position peaked at $10.7M in Q2 2024. 1,395 funds tracked by Wall St. Rank hold NVO as of Q3 2025.

  • Wolverine Trading held 9,629 shares of Novo Nordisk worth $534K as of Q3 2025.
  • Wolverine Trading sold 55,416 Novo Nordisk shares in Q3 2025, an estimated $3.24M.
  • Novo Nordisk made up ﹤0.01% of Wolverine Trading's portfolio in Q3 2025, its #3633 holding.
  • Wolverine Trading first reported a position in Novo Nordisk in Q1 2017 and has held it in 25 quarters since.
  • Wolverine Trading's Novo Nordisk position peaked at $10.7M in Q2 2024.
  • 1,395 funds tracked by Wall St. Rank held Novo Nordisk as of Q3 2025.

Based on Wolverine Trading's 13F filing for Q3 2025, filed 14 Nov 2025.